Human PBMCs
Price range: $79.00 through $1,998.00
MileCell offers high-quality, isolated human peripheral blood mononuclear cells (hPBMCs) from healthy donors, available in fresh and cryopreserved format.
Note:Please select all variant options above.
$$$
Peripheral blood mononuclear cells (PBMCs) are a heterogeneous population of immune cells isolated from peripheral blood, comprising lymphocytes (T cells, B cells, and NK cells) and monocytes. As a physiologically relevant primary cell system, PBMCs serve as a foundational tool for immunology research, drug discovery, and translational medicine across a broad range of study designs.
MileCell's PBMC products are isolated from peripheral blood via standardized density gradient centrifugation, with every lot validated for high purity, viability, and immunophenotyping by flow cytometry. Available in fresh and cryopreserved formats, they can be used in applications spanning immunotoxicity, immunogenicity testing, vaccine development, immune functional assays, and cell therapy research.
Quality
- Purity: ≥90%
- Viability: ≥90%
- Mycoplasma Detection: Negative
- Microbial Testing: Negative
- Viral Screening: Negative for HBV, HIV, HCV, TP
- Zhao Q, Li Y, Zhang H, et al. Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01): a phase II clinical trial. Signal Transduct Target Ther. 2026;11(1):201. doi:10.1038/s41392-026-02668-7.
- Yang Z, Cao S, Zhang J, et al. Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance. Signal Transduct Target Ther. 2026;11(1):139. doi:10.1038/s41392-026-02664-x.
- Li X, Hu J, Zhang T, et al. An in situ generated CAR-M with IFN-γ and negative dominance Sirpα isoform augments hepatocellular carcinoma immunotherapy. J Nanobiotechnology. 2026;24:688. doi:10.1186/s12951-026-04593-x.
- Liu Q, Xiong Q, Xie G, et al. Self-sufficient killing of malignant tumors by an engineered cancer-selective gene circuit. Cell Rep Med. 2026;7(8):102936. doi:10.1016/j.xcrm.2026.102936.
- Fang P, You M, Wen H, et al. Structural basis of nectin-4 recognition by the antibody-drug conjugate 9MW2821. J Biol Chem. 2025;301(12):110816. doi:10.1016/j.jbc.2025.110816.
- Zheng L, Xue R, Ma X, et al. Study on the anti-tumor effect of PDL1-CAR-γδT cells constructed with nanobody sequences on glioblastoma. Am J Cancer Res. 2025;15(11):4780-4794. doi:10.62347/UMII4942.
- Luan R, Lin H, Zhao X, et al. Pan-cancer multi-omics reveals DCAF7 as an immune-modulating prognostic driver and Wnt/β-catenin activator in hepatocellular carcinoma. Clin Transl Med. 2026;16(1). doi:10.1002/ctm2.70572.
- Mi X, Zhu J, Dai Z, et al. HLA-II Expression Marks Activated and Clonally Expanded CD8+ T Cells and Improves Tumor-Reactivity Prediction Across Human Cancers. Int J Mol Sci. 2026;27(18):8338. doi:10.3390/ijms27188338.
- Liu S, Ren Z, Tu Y, et al. FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed T-cell activation. Oncoimmunology. 2026;15(1):2684136. doi:10.1080/2162402X.2026.2684136.
- Guo X, Li J, Bai X, et al. HBx hijacks the miR-19a-3p/BAMBI/TGF-β1 axis to impair the anti-tumour activity of CD4+ T cells in diffuse large B-cell lymphoma. Clin Transl Med. 2026;16(1). doi:10.1002/ctm2.70578.
- Kuang H, Lin CX, Huang J, et al. In vivo Expansion of Regulatory T cells via an Engineered IL-2 Mutein to Suppress Autoimmune Glomerulonephritis. Theranostics. 2026;16(9):4787-4803. doi:10.7150/thno.126588.
- Liu Y, Yin M, Yang Y, et al. MDI1228, a topical pan-JAK inhibitor, disrupts dermal fibroblast-T cell chemokine crosstalk to resolve allergic contact and atopic dermatitis. Front Immunol. 2026;17:1875876. doi:10.3389/fimmu.2026.1875876.
- Wang Z, Guo S, Li J, et al. Identifying Cytokine Motif-Containing, Immunomodulatory Bacterial Proteins in Human Gut Microbiome. Adv Sci (Weinh). 2026;13(29). doi:10.1002/advs.202520332.
- Huang G, He R, Wang W, et al. VSIG4 suppresses antitumor T cell immunity via the SLC3A2-dependent metabolic-ionic checkpoint. J Immunother Cancer. 2026;14(6). doi:10.1136/jitc-2025-013562.
- Wang L, Ding Y, Lv H, et al. The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity. Antib Ther. 2026;9(1):13-23. doi:10.1093/abt/tbaf023.
- Cheng Y, Li Q, Kong Y, et al. An IL-15-modified NKp30×HER2 trispecific NK cell engager enhances NK cell activation and tumor cell killing. J Leukoc Biol. 2025;117(8). doi:10.1093/jleuko/qiaf107.
- Liu, Q., Xiong, Q., Xie, G., Chen, Q., Yang, S., Wu, Y., Zhao, L., Gao, T., Qiu, X., Jiang, J., Wang, X., Shao, J., Xie, M., & Ying, S. (2026). Self‑sufficient killing of malignant tumors by an engineered cancer‑selective gene circuit. Cell Reports Medicine, 7, Article 102936.
- Yang, Z., Cao, S., Zhang, J., Nie, X., Wang, Z., Yang, S., Wang, J., Sun, X., Kuang, X., Huang, H., Wei, Z., Duan, P., Tang, M., Zhang, L., Ren, Z., Lan, X., Fu, Y.-X., Zhang, L., Zhang, X., & Liang, Y. (2026). Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance. Signal Transduction and Targeted Therapy, 11, Article 139.
- Wang, Y., Wang, Y., Yuan, W., Fan, M., Wang, X., Wang, A., Bao, Y., Zhang, Y., Tan, J. C., Wang, J., Liu, J., Huang, T., Han, Z., Pei, B., Chen, L., Ren, Z., Wang, X., Hu, L., Wu, S., … Zhao, X. (2026). Tuning the sensitivity of mechanosensory receptors through histidine scanning. Cell, 189, 1–21.
- Cui, M., Hu, C., Dong, J., Cheng, Y., Sun, B., Fan, C., Wang, L., & Chao, J. (2026). Multimodal DNA nanostructure barcodes for single-cell protein profiling and tumor subtyping. ACS Nano, 20, 5904–5917.
- Ma, Y., Wang, X., Wei, Z., Zhang, Q., Yuan, F., Xu, C., Liu, C., Wang, X., Li, L., & Jiao, Y. (2026). SLC5A11 mediates metformin-induced PD-L1 suppression to enhance cancer immunotherapy through AMPK–IRF1 signaling. Cancer Letters, 644, 218311.
- Wang, K., Li, X., Li, J., Yu, Z., Li, P., Xie, Y., Liu, J., Huang, H., Zhang, S., Zhang, M., Ma, W., Gao, F., Du, X., Wang, J., Capecchi, M. R., & Wu, S. (2026). Basic enables selection-free efficient knockin of large DNA in primary human T cells. Molecular Therapy, 34(4).
- Tian, X., Liu, J., Li, Y., Wang, Y., Luo, Y., He, H., She, Y., Ma, Y., Ding, J., Zhou, P., Li, C., & Shao, F. (2025). Agonists for cytosolic bacterial receptor ALPK1 induce antitumour immunity. Nature.
- Wang, C., Li, J., Tong, Y., Chang, H., Xu, J., Zhu, H., Yin, Y., Meng, M., & Xi, R. (2025). Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associated Tregs, without inducing systemic toxicity. Journal for ImmunoTherapy of Cancer, 13, e012829.
- Wang, S., Li, M., Shen, H., Zhou, W., Sun, J., Tang, Q., Liu, H., Zhang, W., Shen, Z., & Chen, W. (2025). CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy. Journal of Controlled Release.
- Niu, X., Tang, Y., Zhang, G., Zhang, P., Dai, L., Peng, X., & Wan, X. (2025). Flagellin engineering enhances CAR-T cell function by reshaping tumor microenvironment in solid tumors. Journal for ImmunoTherapy of Cancer, 13, e010237.
- Cheng, Y., Li, Q., Kong, Y., Huang, A., Yang, Z., Ying, T., & Wu, Y. (2025). An IL-15-modified NKp30×HER2 trispecific NK cell engager enhances NK cell activation and tumor cell killing. Journal of Leukocyte Biology, 117(8), qiaf107.
- Cheng, B., Li, M., Zheng, J., Liang, J., Li, Y., Liang, R., Tian, H., Zhou, Z., Ding, L., Ren, J., Shi, W., Zhou, W., Hu, H., Meng, L., Liu, K., Cai, L., Shao, X., Fang, L., & Li, H. (2025). Chemically engineered antibodies for autophagy-based receptor degradation. Nature Chemical Biology, 21(6), 855–866.
- Yuan, Y., Wei, Y., Jia, Z., Chu, H., Kong, D., Lei, F., Ye, F., Qian, X., Zhang, J., Zhou, X., Zhu, X., Li, Z., Liang, X., & Chen, W. (2025). Discovery of KBD4466, a selective TLR 7/8 inhibitor, for the treatment of autoimmune diseases. Journal of Medicinal Chemistry.
- Liu, J., Liu, W., Hu, Z., Xing, Z., Sun, G. W., Wang, M., Zhang, S. C., & Zhang, X. R. (2025). Apoferritin Nanoparticle-Based Mass Tags: A Novel Metal Tagging Strategy for Mass Cytometry. Analytical Chemistry.
- Lin, H. L., Ye, S. W., Zhang, S. J., Ge, T., Li, D. J., Huang, L., Zhu, L., & Mu, W. (2024). Optimizing the procedure for manufacturing clinical-grade genetically manipulated natural killer cells for adoptive immunotherapy. Cytotherapy.
- Lin, H., Zhang, L., Ge, T., An, N., Yang, Y., Zhang, Y., & Mu, W. (2025). Engineering CD5-targeting CAR-NK cells from peripheral blood for the treatment of CD5-positive hematological malignancies. Journal of Translational Medicine, 23(1), 409.
- Liu, W., Hu, Z., Jiang, W., Liu, J., Sun, G., Zhang, S., & Zhang, X. (2025). Nucleotide-based elemental mass probes for high-sensitive single-cell mass cytometry. Analytical Chemistry, 97(15), 6234–6242.
- Li, Z., Song, P., Liu, Y., Sun, X., Zhai, X., & Rao, Y. (2025). Developing potent anti-inflammatory IRAK4-targeting PROTACs with simplified CRBN ligands. Journal of Medicinal Chemistry, 68(5), 3456–3468.
- Tang, Q., Li, M., Wang, S., Li, J., Cao, S., Liu, H., Wu, Y., Chen, Y., Shen, H., Zhang, W., Shen, Z., & Chen, W. (2024). Room-temperature-stable immunosuppressive nanovesicles for mitigating immunopathology and streamlining cardioprotection post-infarction. Chemical Engineering Journal. Advance online publication. https://doi.org/10.1016/j.cej.2024.15703
- Shen, Y., Jin, S.-J., Chen, Y.-C., Liu, W.-H., Li, Y.-M., Zhao, W.-Y., Xu, Y.-C., Chen, S.-Q., & Zhao, W.-B. (2023). Improving the tumor selectivity of T cell engagers by logic-gated dual tumor-targeting. Pharmacological Research, 192, 106781.
- Wu, S., Luo, Q., Li, F., Zhang, S., Zhang, C., Liu, J., Shao, B., Hong, Y., Tan, T., Dong, X., & Chen, B. (2024). Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms. British Journal of Haematology. Advance online publication.
- Liu, S., Miersch, S., Li, P., Bai, B., Liu, C., Qin, W., Su, J., Huang, H., Pan, J., Sidhu, S. S., & Wu, D. (2020). A synthetic human antibody antagonizes IL-18Rβ signaling through an allosteric mechanism. Journal of Molecular Biology, 432(8), 2512-2523.
- Cheng, J., Ge, T., Zhu, X., Wang, J., Zeng, Y., Mu, W., Cai, H., Dai, Z., Jin, J., Yang, Y., Hu, G., Mao, X., Zhou, J., Zhu, L., & Huang, L. (2023). Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia. Cancer Immunology, Immunotherapy, 72(5), 1123-1137. https://doi.org/10.1007/s00262-023-03422-6
- Cheng, J., Zhao, Y., Hu, H., Tang, L., Zeng, Y., Deng, X., Ding, S., Guo, A.-Y., Li, Q., & Zhu, X. (2023). Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics. Cancer Immunology, Immunotherapy. Advance online publication. https://doi.org/10.1007/s00262-023-03475-7
- Amissah, O. B., Chen, W., Habimana, J. D., Sun, Y., Lin, L., Liu, Y., Wang, L., Liu, Z., Mukama, O., Basnet, R., Liu, H., Li, J., Ding, X., Lv, L., Chen, M., Liang, Y., Huang, R., & Li, Z. (2024). NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. Cancer Cell International, 24(1), 64.
- Chen, C., Cui, H., Liu, H., Wu, Y., Ding, N., Weng, Y., Zhang, W., & Cui, Y. (2022). Role of epidermal growth factor receptor-specific CAR-T cells in the suppression of esophageal squamous cell carcinoma. Cancers, 14(24), 6021.
- Lei, X., Huang, A., Chen, D., Wang, X., Ji, R., Wang, J., Zhang, Y., Zhang, Y., Lu, S., Zhang, K., Chen, Q., Zhang, Y., & Yin, H. (2024). Rapid generation of long, chemically modified pegRNAs for prime editing. Nature Biotechnology. Advance online publication.
- Xu, Z., Wang, R., Xu, Y., Qiu, R., Chen, J., Liu, L., & Qian, Q. (2025). Comparative analysis and process optimization for manufacturing CAR-T using the PiggyBac system derived from cryopreserved versus fresh PBMCs. Scientific Reports, 15(1), 12345.
